- Home
- FCO vs UNCY Comparison
FCO vs UNCY Comparison
Compare FCO & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCO
- UNCY
- Stock Information
- Founded
- FCO 1991
- UNCY 2016
- Country
- FCO United Kingdom
- UNCY United States
- Employees
- FCO N/A
- UNCY N/A
- Industry
- FCO Investment Managers
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- FCO Finance
- UNCY Health Care
- Exchange
- FCO Nasdaq
- UNCY Nasdaq
- Market Cap
- FCO 80.3M
- UNCY 70.3M
- IPO Year
- FCO N/A
- UNCY 2021
- Fundamental
- Price
- FCO $5.98
- UNCY $0.62
- Analyst Decision
- FCO
- UNCY Strong Buy
- Analyst Count
- FCO 0
- UNCY 4
- Target Price
- FCO N/A
- UNCY $5.50
- AVG Volume (30 Days)
- FCO 100.1K
- UNCY 1.3M
- Earning Date
- FCO 01-01-0001
- UNCY 11-13-2024
- Dividend Yield
- FCO 14.96%
- UNCY N/A
- EPS Growth
- FCO N/A
- UNCY N/A
- EPS
- FCO 0.43
- UNCY N/A
- Revenue
- FCO N/A
- UNCY N/A
- Revenue This Year
- FCO N/A
- UNCY N/A
- Revenue Next Year
- FCO N/A
- UNCY N/A
- P/E Ratio
- FCO $12.30
- UNCY N/A
- Revenue Growth
- FCO N/A
- UNCY N/A
- 52 Week Low
- FCO $4.73
- UNCY $0.20
- 52 Week High
- FCO $6.63
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- FCO 54.52
- UNCY 40.04
- Support Level
- FCO $5.91
- UNCY $0.61
- Resistance Level
- FCO $5.98
- UNCY $0.73
- Average True Range (ATR)
- FCO 0.10
- UNCY 0.07
- MACD
- FCO 0.01
- UNCY -0.02
- Stochastic Oscillator
- FCO 71.05
- UNCY 15.66
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.